Procter & Gamble Health Limited (PGHL) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Procter & Gamble Health Limited enters Q1 FY27 with strong momentum in its VMS portfolio, supported by structural growth in preventive healthcare and e-commerce channel expansion. Investors will be focused on whether the company can maintain its double-digit revenue growth trajectory and manage input cost volatility, particularly following recent spikes in Vitamin E prices.

Procter & Gamble Health Limited Q1 Results Date and Time

The board meeting is scheduled for August 06, 2026, to consider the audited financial results and recommend dividend for FY2026.

The company held a virtual analyst and institutional investor meeting on June 18, 2026, at 2:30 PM IST.

The board has recommended a final dividend of Rs. 45 per share, which is subject to shareholder approval at the 59th AGM and payable on or before September 25, 2026.

What to expect from Procter & Gamble Health Limited's Q1 FY27 results

Procter & Gamble Health is expected to maintain balanced growth momentum in Q1 FY27, building on the 19.1% YoY revenue growth achieved in Q4 FY26. While the broader pharma branded formulations sector reported a median revenue growth of 25.3% YoY for the quarter, PGHL's performance will be tested by a 71% QoQ spike in domestic Vitamin E prices that impacts the Evion brand. Management's strategic focus remains on its five-pillar integrated growth strategy, which delivered Rs. 35 crore in productivity savings during FY26 and supported market share gains in the VMS segment. Future margin trajectory will likely be influenced by the company's ability to navigate these input cost pressures while continuing its expansion into extra-urban and digital channels like quick commerce.

Key Things To Watch

Volume and Revenue Growth: Monitoring the sustainability of growth trends established in FY26.

• Volume growth trajectory: assessing if the mid-single-digit growth from FY26 accelerated in Q1 FY27
• Revenue growth sustainability: evaluating if the 16% YoY growth pace from FY26 can be maintained

Input Cost and Margin Management: Addressing specific cost headwinds impacting the product portfolio.

• Vitamin E cost pass-through: evaluating the impact of the 71% QoQ price spike on Evion brand margins
• Productivity savings: seeking updates on any new cost-optimisation targets for FY27 following the Rs. 35 Cr savings in FY26

Strategic Initiatives and Channel Mix: Tracking the performance of new launches and evolving distribution channels.

• Channel evolution: assessing the contribution trend from e-pharmacy and quick commerce channels

Regulatory and Operational Environment: Monitoring external factors influencing pricing and management structure.

• NPPA pricing: evaluating the impact of the May 31, 2026, retail price fixation on Vitamin D3 and calcium supplements
• Management transition: assessing the impact of senior management reassignments effective July 1, 2026, on sales execution